<?xml version='1.0' encoding='utf-8'?>
<document id="19346885"><sentence text="Posaconazole-increased vincristine neurotoxicity in a child: a case report."><entity charOffset="0-12" id="DDI-PubMed.19346885.s1.e0" text="Posaconazole" /><entity charOffset="23-34" id="DDI-PubMed.19346885.s1.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.19346885.s1.e0" e2="DDI-PubMed.19346885.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19346885.s1.e0" e2="DDI-PubMed.19346885.s1.e1" /></sentence><sentence text="A 9-year-old girl was managed according to the COPRALL 04 protocol for treatment of a relapse of acute lymphoblastic leukemia" /><sentence text=" Owing to a previous case of disseminated fusariosis, posaconazole was started 5 days before initiation of chemotherapy"><entity charOffset="54-66" id="DDI-PubMed.19346885.s3.e0" text="posaconazole" /></sentence><sentence text=" Six days after the last dose of vincristine, the child reported symptoms of severe peripheral neuropathy, abdominal cramps, and constipation"><entity charOffset="33-44" id="DDI-PubMed.19346885.s4.e0" text="vincristine" /></sentence><sentence text=" After this, she developed fluctuations in her level of consciousness and seizures" /><sentence text=" After cessation of therapy with posaconazole, a complete resolution of the above occurred within 7 days"><entity charOffset="33-45" id="DDI-PubMed.19346885.s6.e0" text="posaconazole" /></sentence><sentence text=" This case illustrates the possibility of vincristine toxicity exacerbated by coadministration of posaconazole"><entity charOffset="42-53" id="DDI-PubMed.19346885.s7.e0" text="vincristine" /><entity charOffset="98-110" id="DDI-PubMed.19346885.s7.e1" text="posaconazole" /><pair ddi="false" e1="DDI-PubMed.19346885.s7.e0" e2="DDI-PubMed.19346885.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19346885.s7.e0" e2="DDI-PubMed.19346885.s7.e1" /></sentence><sentence text=" As posaconazole is an inhibitor of the isoenzyme CYP3A4, interactions with drugs that are metabolized via this pathway, such as vincristine, can be anticipated"><entity charOffset="4-16" id="DDI-PubMed.19346885.s8.e0" text="posaconazole" /><entity charOffset="129-140" id="DDI-PubMed.19346885.s8.e1" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.19346885.s8.e0" e2="DDI-PubMed.19346885.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19346885.s8.e0" e2="DDI-PubMed.19346885.s8.e1" /></sentence><sentence text=" Another possibility is that, like itraconazole, posaconazole may also inhibit P-glycoprotein-mediated vincristine efflux"><entity charOffset="35-47" id="DDI-PubMed.19346885.s9.e0" text="itraconazole" /><entity charOffset="49-61" id="DDI-PubMed.19346885.s9.e1" text="posaconazole" /><entity charOffset="103-114" id="DDI-PubMed.19346885.s9.e2" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.19346885.s9.e0" e2="DDI-PubMed.19346885.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19346885.s9.e0" e2="DDI-PubMed.19346885.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19346885.s9.e0" e2="DDI-PubMed.19346885.s9.e2" /><pair ddi="false" e1="DDI-PubMed.19346885.s9.e1" e2="DDI-PubMed.19346885.s9.e1" /><pair ddi="false" e1="DDI-PubMed.19346885.s9.e1" e2="DDI-PubMed.19346885.s9.e2" /></sentence><sentence text=" Although case reports of neurotoxicity owing to possible interaction between itraconazole and vincristine exist in the literature, only 1 case report relating to the possible interaction between posaconazole and vincristine exists"><entity charOffset="78-90" id="DDI-PubMed.19346885.s10.e0" text="itraconazole" /><entity charOffset="95-106" id="DDI-PubMed.19346885.s10.e1" text="vincristine" /><entity charOffset="196-208" id="DDI-PubMed.19346885.s10.e2" text="posaconazole" /><entity charOffset="213-224" id="DDI-PubMed.19346885.s10.e3" text="vincristine" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e0" e2="DDI-PubMed.19346885.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e0" e2="DDI-PubMed.19346885.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e0" e2="DDI-PubMed.19346885.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e0" e2="DDI-PubMed.19346885.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e1" e2="DDI-PubMed.19346885.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e1" e2="DDI-PubMed.19346885.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e1" e2="DDI-PubMed.19346885.s10.e3" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e2" e2="DDI-PubMed.19346885.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19346885.s10.e2" e2="DDI-PubMed.19346885.s10.e3" /></sentence><sentence text=" Clinicians should be made aware of this possible drug-drug interaction" /><sentence text="" /></document>